Miglitol

CHF 72.00
In stock
SYN-3027-M0011 mgCHF 72.00
SYN-3027-M0055 mgCHF 108.00
SYN-3027-M01010 mgCHF 132.00
SYN-3027-M05050 mgCHF 461.00
SYN-3027-M100100 mgCHF 814.00
 
More Information
Product Details
Synonyms Glyset
Product Type Chemical
Properties
Formula C8H17NO5
MW 207.2
CAS 72432-03-2
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: N/A | Kinase Group: | Substrate: N/A

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key IBAQFPQHRJAVAV-ULAWRXDQSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Miglitol (Glyset) is an oral anti-diabetic drug that acts by inhibiting the breakdown of complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases.
Product References
  1. Miglitol, a new alpha-glucosidase inhibitor: J.P. Sels, et al.; Expert Opin. Pharmacother. 1, 149 (1999)
  2. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats: T. Goda, et al.; Br. J. Nutr. 98, 702 (2007)
  3. Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase: C. Aoki, et al.; J. Pharmacol. Sci. 120, 121 (2012)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.